The Journal of Immunology · 2003 · 109 citations · 30 references
Life SciencesImmunologyOncologyApoptosisCancer ImmunologyInnate ImmunityAntiviral ImmunityCancer Cell SignalingCancer ImmunotherapyCytokines In Tumor ImmunityDeath ReceptorsOncogenic VirusesAnticancer ActivityAntiviral Signaling PathwaysImmunostimulatory AgentsInnate Antitumor ImmunityTrail-mediated ApoptosisTumor Necrosis Factor-related Apoptosis-inducing Ligand ReceptorsTumor Necrosis Factor-related Apoptotic SignalingUv Inactivation
The Newcastle disease virus (NDV) has antineoplastic and immunostimulatory properties, and it is currently clinically tested in anticancer therapy. However, the tumoricidal mechanisms of NDV tumor therapy are not fully understood. The results presented here demonstrate that NDV-stimulated human monocytes (Mphi) kill various human tumor cell lines and that this tumoricidal activity is mediated by TRAIL. In contrast to soluble TRAIL-R2-Fc, soluble CD95-Fc and TNF-R2-Fc showed only minimal blocking of the antitumor effect. TRAIL expression is induced on human Mphi after stimulation with NDV and UV-inactivated NDV. These results show that TRAIL induction on human Mphi after NDV stimulation is independent from viral replication and that TRAIL mediates the tumoricidal activity of NDV-stimulated human Mphi.
30
Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo
Henning Walczak, Robert E. Miller, K. Ariail et al. · Nature Medicine · 1999 · 2.5K citations
Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi, Roger Pai, Sharon Fong et al. · Journal of Clinical Investigation · 1999 · 2.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
Jens Dhein, Henning Walczak, Caroline Bäumler et al. · Nature · 1995 · 1.6K citations
TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL
Henning Walczak · The EMBO Journal · 1997 · 1.1K citations · Full text